RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024
09 sept. 2024 07h55 HE
|
RIGImmune
Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...
Ancilia Biosciences Announces Closing of $4.2 Million Financing
17 juil. 2024 07h00 HE
|
Ancilia Biosciences
Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.
[Latest] Global Crop Protection Chemicals Market Size/Share Worth USD 98.5 Billion by 2032 at a 4.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
13 févr. 2024 11h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Crop Protection Chemicals Market Size, Trends and Insights By Type (Herbicides,...
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
16 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
08 févr. 2023 16h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
07 déc. 2022 08h00 HE
|
RIGImmune
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...
Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
27 janv. 2022 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
20 nov. 2020 09h10 HE
|
Auris Medical AG
Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Moleaer & ASU confirm nanobubbles produce reactive oxygen species, hydroxyl radicals, known to eliminate hard-to-kill pathogens
26 oct. 2020 12h00 HE
|
Moleaer Inc.
Carson, CA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Moleaer, a leading nanobubble technology company, in collaboration with Arizona State University’s (ASU) Research Center for Nanotechnology Enabled...
Coronavirus (COVID-19) Tracking Now Integrated into Conduent Maven® Platform
05 mars 2020 03h30 HE
|
Conduent Business Services, LLC
Maven’s COVID-19 tracking software module makes required reporting by state and local health authorities more efficient and cost-effective Company will demonstrate Maven’s capabilities at HIMSS...